HSP90 inhibition suppresses lipopolysaccharide-induced lung inflammation in vivo

Andrew Lilja, Clare E. Weeden, Kate McArthur, Thao Nguyen, Alastair Donald, Zi Xin Wong, Lovisa Dousha, Steve Bozinovski, Ross Vlahos, Christopher J. Burns, Marie-Liesse Labat, Gary P. Anderson

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Inflammation is an important component of cancer diathesis and treatment-refractory inflammation is a feature of many chronic degenerative lung diseases. HSP90 is a 90kDa protein which functions as an ATP-dependent molecular chaperone that regulates the signalling conformation and expression of multiple protein client proteins especially oncogenic mediators. HSP90 inhibitors are in clinical development as cancer therapies but the myeleosuppressive and neutropenic effect of first generation geldanamycin-class inhibitors has confounded studies on the effects on HSP90 inhibitors on inflammation. To address this we assessed the ability of Ganetespib, a non-geldanamycin HSP90 blocker, to suppress lipopolysaccharide (LPS)-induced cellular infiltrates, proteases and inflammatory mediator and transcriptional profiles. Ganetespib (10-100mg/kg, i.v.) did not directly cause myelosuppression, as assessed by video micrography and basal blood cell count, but it strongly and dosedependently suppressed LPS-induced neutrophil mobilization into blood and neutrophil- and mononuclear cell-rich steroid-refractory lung inflammation. Ganetespib also suppressed B cell and NK cell accumulation, inflammatory cytokine and chemokine induction and MMP9 levels. These data identify non-myelosuppresssive HSP90 inhibitors as potential therapies for inflammatory diseases refractory to conventional therapy, in particular those of the lung.

Original languageEnglish (US)
Article numbere0114975
JournalPloS one
Volume10
Issue number1
DOIs
StatePublished - Jan 23 2015
Externally publishedYes

Fingerprint

Refractory materials
lipopolysaccharides
Lipopolysaccharides
Pneumonia
inflammation
lungs
Inflammation
Neutrophils
Blood
Cells
therapeutics
neutrophils
Cohort Effect
Pulmonary diseases
Proteins
Molecular Chaperones
Blood Cell Count
Disease Susceptibility
Chemokines
Natural Killer Cells

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

Lilja, A., Weeden, C. E., McArthur, K., Nguyen, T., Donald, A., Wong, Z. X., ... Anderson, G. P. (2015). HSP90 inhibition suppresses lipopolysaccharide-induced lung inflammation in vivo. PloS one, 10(1), [e0114975]. https://doi.org/10.1371/journal.pone.0114975

HSP90 inhibition suppresses lipopolysaccharide-induced lung inflammation in vivo. / Lilja, Andrew; Weeden, Clare E.; McArthur, Kate; Nguyen, Thao; Donald, Alastair; Wong, Zi Xin; Dousha, Lovisa; Bozinovski, Steve; Vlahos, Ross; Burns, Christopher J.; Labat, Marie-Liesse; Anderson, Gary P.

In: PloS one, Vol. 10, No. 1, e0114975, 23.01.2015.

Research output: Contribution to journalArticle

Lilja, A, Weeden, CE, McArthur, K, Nguyen, T, Donald, A, Wong, ZX, Dousha, L, Bozinovski, S, Vlahos, R, Burns, CJ, Labat, M-L & Anderson, GP 2015, 'HSP90 inhibition suppresses lipopolysaccharide-induced lung inflammation in vivo', PloS one, vol. 10, no. 1, e0114975. https://doi.org/10.1371/journal.pone.0114975
Lilja A, Weeden CE, McArthur K, Nguyen T, Donald A, Wong ZX et al. HSP90 inhibition suppresses lipopolysaccharide-induced lung inflammation in vivo. PloS one. 2015 Jan 23;10(1). e0114975. https://doi.org/10.1371/journal.pone.0114975
Lilja, Andrew ; Weeden, Clare E. ; McArthur, Kate ; Nguyen, Thao ; Donald, Alastair ; Wong, Zi Xin ; Dousha, Lovisa ; Bozinovski, Steve ; Vlahos, Ross ; Burns, Christopher J. ; Labat, Marie-Liesse ; Anderson, Gary P. / HSP90 inhibition suppresses lipopolysaccharide-induced lung inflammation in vivo. In: PloS one. 2015 ; Vol. 10, No. 1.
@article{d8139423f2bb46a99c35bd158baee7d5,
title = "HSP90 inhibition suppresses lipopolysaccharide-induced lung inflammation in vivo",
abstract = "Inflammation is an important component of cancer diathesis and treatment-refractory inflammation is a feature of many chronic degenerative lung diseases. HSP90 is a 90kDa protein which functions as an ATP-dependent molecular chaperone that regulates the signalling conformation and expression of multiple protein client proteins especially oncogenic mediators. HSP90 inhibitors are in clinical development as cancer therapies but the myeleosuppressive and neutropenic effect of first generation geldanamycin-class inhibitors has confounded studies on the effects on HSP90 inhibitors on inflammation. To address this we assessed the ability of Ganetespib, a non-geldanamycin HSP90 blocker, to suppress lipopolysaccharide (LPS)-induced cellular infiltrates, proteases and inflammatory mediator and transcriptional profiles. Ganetespib (10-100mg/kg, i.v.) did not directly cause myelosuppression, as assessed by video micrography and basal blood cell count, but it strongly and dosedependently suppressed LPS-induced neutrophil mobilization into blood and neutrophil- and mononuclear cell-rich steroid-refractory lung inflammation. Ganetespib also suppressed B cell and NK cell accumulation, inflammatory cytokine and chemokine induction and MMP9 levels. These data identify non-myelosuppresssive HSP90 inhibitors as potential therapies for inflammatory diseases refractory to conventional therapy, in particular those of the lung.",
author = "Andrew Lilja and Weeden, {Clare E.} and Kate McArthur and Thao Nguyen and Alastair Donald and Wong, {Zi Xin} and Lovisa Dousha and Steve Bozinovski and Ross Vlahos and Burns, {Christopher J.} and Marie-Liesse Labat and Anderson, {Gary P.}",
year = "2015",
month = "1",
day = "23",
doi = "10.1371/journal.pone.0114975",
language = "English (US)",
volume = "10",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "1",

}

TY - JOUR

T1 - HSP90 inhibition suppresses lipopolysaccharide-induced lung inflammation in vivo

AU - Lilja, Andrew

AU - Weeden, Clare E.

AU - McArthur, Kate

AU - Nguyen, Thao

AU - Donald, Alastair

AU - Wong, Zi Xin

AU - Dousha, Lovisa

AU - Bozinovski, Steve

AU - Vlahos, Ross

AU - Burns, Christopher J.

AU - Labat, Marie-Liesse

AU - Anderson, Gary P.

PY - 2015/1/23

Y1 - 2015/1/23

N2 - Inflammation is an important component of cancer diathesis and treatment-refractory inflammation is a feature of many chronic degenerative lung diseases. HSP90 is a 90kDa protein which functions as an ATP-dependent molecular chaperone that regulates the signalling conformation and expression of multiple protein client proteins especially oncogenic mediators. HSP90 inhibitors are in clinical development as cancer therapies but the myeleosuppressive and neutropenic effect of first generation geldanamycin-class inhibitors has confounded studies on the effects on HSP90 inhibitors on inflammation. To address this we assessed the ability of Ganetespib, a non-geldanamycin HSP90 blocker, to suppress lipopolysaccharide (LPS)-induced cellular infiltrates, proteases and inflammatory mediator and transcriptional profiles. Ganetespib (10-100mg/kg, i.v.) did not directly cause myelosuppression, as assessed by video micrography and basal blood cell count, but it strongly and dosedependently suppressed LPS-induced neutrophil mobilization into blood and neutrophil- and mononuclear cell-rich steroid-refractory lung inflammation. Ganetespib also suppressed B cell and NK cell accumulation, inflammatory cytokine and chemokine induction and MMP9 levels. These data identify non-myelosuppresssive HSP90 inhibitors as potential therapies for inflammatory diseases refractory to conventional therapy, in particular those of the lung.

AB - Inflammation is an important component of cancer diathesis and treatment-refractory inflammation is a feature of many chronic degenerative lung diseases. HSP90 is a 90kDa protein which functions as an ATP-dependent molecular chaperone that regulates the signalling conformation and expression of multiple protein client proteins especially oncogenic mediators. HSP90 inhibitors are in clinical development as cancer therapies but the myeleosuppressive and neutropenic effect of first generation geldanamycin-class inhibitors has confounded studies on the effects on HSP90 inhibitors on inflammation. To address this we assessed the ability of Ganetespib, a non-geldanamycin HSP90 blocker, to suppress lipopolysaccharide (LPS)-induced cellular infiltrates, proteases and inflammatory mediator and transcriptional profiles. Ganetespib (10-100mg/kg, i.v.) did not directly cause myelosuppression, as assessed by video micrography and basal blood cell count, but it strongly and dosedependently suppressed LPS-induced neutrophil mobilization into blood and neutrophil- and mononuclear cell-rich steroid-refractory lung inflammation. Ganetespib also suppressed B cell and NK cell accumulation, inflammatory cytokine and chemokine induction and MMP9 levels. These data identify non-myelosuppresssive HSP90 inhibitors as potential therapies for inflammatory diseases refractory to conventional therapy, in particular those of the lung.

UR - http://www.scopus.com/inward/record.url?scp=84921826944&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84921826944&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0114975

DO - 10.1371/journal.pone.0114975

M3 - Article

VL - 10

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 1

M1 - e0114975

ER -